Pcdhb22 Inhibitors
Pcdhb22 inhibitors are specialized compounds designed to target protocadherin beta 22 (Pcdhb22), a protein that belongs to the protocadherin beta subfamily within the cadherin superfamily of cell adhesion molecules. Pcdhb22 is predominantly expressed in the nervous system and is involved in mediating calcium-dependent cell-cell adhesion, which is crucial for the establishment and maintenance of specific neuronal connections. The protein features multiple extracellular cadherin domains that facilitate homophilic interactions, a single transmembrane region, and a unique cytoplasmic tail that contributes to intracellular signaling pathways. By interacting with Pcdhb22, inhibitors can modulate its adhesive properties and influence neural connectivity and signaling processes.
The chemical class of Pcdhb22 inhibitors encompasses molecules specifically engineered to bind to functional domains of the Pcdhb22 protein. These inhibitors may include small organic molecules, peptides, or peptidomimetics designed to interact with the extracellular cadherin repeats, thereby disrupting the protein's ability to engage in homophilic or heterophilic interactions essential for neuronal adhesion. Alternatively, some inhibitors might target the cytoplasmic tail to affect downstream signaling events associated with Pcdhb22. The development of these compounds involves advanced methodologies such as structure-based drug design, computational modeling, and high-throughput screening techniques to identify and optimize molecules with high specificity and affinity for Pcdhb22. Researchers utilize these inhibitors as valuable tools to study the molecular mechanisms underlying neuronal development, synaptic specificity, and the complex architecture of neural networks in the brain.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
This histone deacetylase inhibitor could lead to an increase in acetylated histones, which may result in a condensed chromatin state at the Pcdhb22 gene locus, thereby hindering the access of transcription machinery and downregulating Pcdhb22 expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By incorporating into DNA and inhibiting DNA methyltransferases, 5-Azacytidine could decrease methylation levels of the Pcdhb22 gene promoter, leading to decreased expression of the Pcdhb22 gene due to changes in transcriptional control. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
As a non-nucleoside DNA methyltransferase inhibitor, RG 108 could specifically target the methylation pattern of the Pcdhb22 gene, potentially reducing expression levels by altering promoter methylation status and reducing transcription factor binding affinity. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Functioning similarly to 5-Azacytidine, 5-Aza-2′-Deoxycytidine could reduce the methylation status of the Pcdhb22 promoter, resulting in decreased transcriptional initiation and lower Pcdhb22 mRNA levels. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid might lead to hyperacetylation of histones at the Pcdhb22 locus, which could suppress the initiation of transcription of the Pcdhb22 gene by changing the chromatin landscape to a more repressive state. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 selectively inhibits class I HDACs, which might result in a specific pattern of histone acetylation at the Pcdhb22 gene regulatory regions, leading to transcriptional repression of Pcdhb22. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
By binding to GC-rich sequences in DNA, Mithramycin A could block transcription factor binding sites upstream of the Pcdhb22 gene, leading to a decrease in Pcdhb22 mRNA synthesis. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
This chemical intercalates between DNA base pairs, disrupting the function of RNA polymerase and leading to a blockade of RNA synthesis, which would decrease Pcdhb22 mRNA levels. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which could lead to a reduction in the translation of proteins involved in the expression of Pcdhb22, resulting in decreased levels of Pcdhb22 protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
As a PI3K inhibitor, LY 294002 would decrease the activity of the Akt signaling pathway, potentially leading to a reduction in transcriptional activity of genes like Pcdhb22 that may be downstream targets. | ||||||